Gyre Therapeutics, Inc.
GYRE
$6.13
$0.081.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.69M | -1.72M | 3.61M | 442.00K | 2.70M |
| Total Depreciation and Amortization | 672.00K | 695.00K | 649.00K | 641.00K | 535.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.77M | 5.13M | 2.85M | 1.48M | 2.26M |
| Change in Net Operating Assets | 9.43M | -9.73M | -2.43M | -476.00K | -5.63M |
| Cash from Operations | 3.18M | -5.63M | 4.68M | 2.09M | -129.00K |
| Capital Expenditure | -178.00K | -144.00K | -668.00K | -256.00K | -122.00K |
| Sale of Property, Plant, and Equipment | 6.00K | 11.00K | 0.00 | 18.00K | 1.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.88M | 1.98M | -579.00K | -2.80M | 2.09M |
| Cash from Investing | -3.06M | 1.85M | -1.25M | -3.04M | 1.97M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 21.00K | 318.00K | 50.00K | 24.03M | 1.47M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 315.00K | -1.68M | -121.00K |
| Cash from Financing | 21.00K | 318.00K | 365.00K | 22.35M | 1.34M |
| Foreign Exchange rate Adjustments | 285.00K | 127.00K | 117.00K | 49.00K | 50.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 431.00K | -3.33M | 3.91M | 21.45M | 3.23M |